Definium Therapeutics is trading 4.2% down at $38.64 as broader risk-off sentiment weighs on equities. - The Nasdaq Composite is down 1.10%, while rising crude oil and Treasury yields are pressuring growth-oriented valuations. - Definium Therapeutics is presenting positive DT120 Phase 3 data at the TD Cowen summit on September 23; no negative company-specific announcement was identified.